| Year |
Citation |
Score |
| 2023 |
Maalouf KE, Vaine CA, Frederick DM, Yoshinaga A, Obuchi W, Mahjoum S, Nieland L, Al Ali J, Bragg DC, Breakefield XO, Breyne K. Tracking human neurologic disease status in mouse brain/plasma using reporter-tagged, EV-associated biomarkers. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 37198883 DOI: 10.1016/j.ymthe.2023.05.011 |
0.597 |
|
| 2022 |
Prabhakar S, Beauchamp RL, Cheah PS, Yoshinaga A, Haidar EA, Lule S, Mani G, Maalouf K, Stemmer-Rachamimov A, Jung DH, Welling DB, Giovannini M, Plotkin SR, Maguire CA, Ramesh V, ... Breakefield XO, et al. Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Molecular Therapy. Methods & Clinical Development. 26: 169-180. PMID 35846573 DOI: 10.1016/j.omtm.2022.06.012 |
0.649 |
|
| 2021 |
Cheah PS, Prabhakar S, Yellen D, Beauchamp RL, Zhang X, Kasamatsu S, Bronson RT, Thiele EA, Kwiatkowski DJ, Stemmer-Rachamimov A, György B, Ling KH, Kaneki M, Tannous BA, Ramesh V, ... ... Breakefield XO, et al. Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Science Advances. 7. PMID 33523984 DOI: 10.1126/sciadv.abb1703 |
0.632 |
|
| 2020 |
Al Ali J, Vaine CA, Shah S, Campion L, Hakoum A, Supnet ML, Acuña P, Aldykiewicz G, Multhaupt-Buell T, Ganza NGM, Lagarde JBB, De Guzman JK, Go C, Currall B, Trombetta B, ... ... Breakefield XO, et al. TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32975318 DOI: 10.1002/mds.28305 |
0.552 |
|
| 2020 |
Abels ER, Maas SLN, Tai E, Ting DT, Broekman MLD, Breakefield XO, El Khoury J. GlioM&M: Web-based tool for studying circulating and infiltrating monocytes and macrophages in glioma. Scientific Reports. 10: 9898. PMID 32555306 DOI: 10.1038/s41598-020-66728-w |
0.313 |
|
| 2020 |
Cruz L, György B, Cheah PS, Kleinstiver BP, Eimer WA, Garcia SP, Sharma N, Ozelius LJ, Bragg DC, Joung JK, Norberto de Souza O, Macedo Timmers LFS, Breakefield XO. Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function. Molecular Therapy. Nucleic Acids. 21: 1-12. PMID 32502938 DOI: 10.1016/J.Omtn.2020.05.009 |
0.624 |
|
| 2020 |
O'Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nature Reviews. Molecular Cell Biology. PMID 32457507 DOI: 10.1038/s41580-020-0251-y |
0.331 |
|
| 2020 |
Maas SLN, Abels ER, Van De Haar LL, Zhang X, Morsett L, Sil S, Guedes J, Sen P, Prabhakar S, Hickman SE, Lai CP, Ting DT, Breakefield XO, Broekman MLD, El Khoury J. Glioblastoma hijacks microglial gene expression to support tumor growth. Journal of Neuroinflammation. 17: 120. PMID 32299465 DOI: 10.1186/s12974-020-01797-2 |
0.359 |
|
| 2020 |
Lucero R, Zappulli V, Sammarco A, Murillo OD, Cheah PS, Srinivasan S, Tai E, Ting DT, Wei Z, Roth ME, Laurent LC, Krichevsky AM, Breakefield XO, Milosavljevic A. Glioma-Derived miRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells. Cell Reports. 30: 2065-2074.e4. PMID 32075753 DOI: 10.1016/j.celrep.2020.01.073 |
0.325 |
|
| 2020 |
Yekula A, Minciacchi VR, Morello M, Shao H, Park Y, Zhang X, Muralidharan K, Freeman MR, Weissleder R, Lee H, Carter B, Breakefield XO, Di Vizio D, Balaj L. Large and small extracellular vesicles released by glioma cells and . Journal of Extracellular Vesicles. 9: 1689784. PMID 31839905 DOI: 10.1080/20013078.2019.1689784 |
0.329 |
|
| 2019 |
Candelario KM, Balaj L, Zheng T, Skog J, Scheffler B, Breakefield X, Schüle B, Steindler DA. Exosome/Microvesicle Content is Altered in LRRK2 Mutant iPSC-derived Neural Cells. The Journal of Comparative Neurology. PMID 31743443 DOI: 10.1002/Cne.24819 |
0.356 |
|
| 2019 |
Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski MP, Volak A, Spirig SE, Muller A, Sousa AA, Tsai SQ, Bengtsson NE, Lööv C, Ingelsson M, Chamberlain JS, Corey DP, Aryee MJ, ... ... Breakefield XO, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nature Communications. 10: 4439. PMID 31570731 DOI: 10.1038/S41467-019-12449-2 |
0.629 |
|
| 2019 |
Prabhakar S, Cheah PS, Zhang X, Zinter M, Gianatasio M, Hudry E, Bronson RT, Kwiatkowski DJ, Stemmer-Rachamimov A, Maguire CA, Sena-Esteves M, Tannous BA, Breakefield XO. Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy. Methods & Clinical Development. 15: 18-26. PMID 31534984 DOI: 10.1016/J.Ibror.2019.07.1575 |
0.659 |
|
| 2019 |
Abels ER, Maas SLN, Nieland L, Wei Z, Cheah PS, Tai E, Kolsteeg CJ, Dusoswa SA, Ting DT, Hickman S, El Khoury J, Krichevsky AM, Broekman MLD, Breakefield XO. Glioblastoma-Associated Microglia Reprogramming Is Mediated by Functional Transfer of Extracellular miR-21. Cell Reports. 28: 3105-3119.e7. PMID 31533034 DOI: 10.1016/j.celrep.2019.08.036 |
0.332 |
|
| 2019 |
Wiklander OPB, Brennan MÁ, Lötvall J, Breakefield XO, El Andaloussi S. Advances in therapeutic applications of extracellular vesicles. Science Translational Medicine. 11. PMID 31092696 DOI: 10.1126/scitranslmed.aav8521 |
0.302 |
|
| 2019 |
Ricklefs FL, Maire CL, Reimer R, Dührsen L, Kolbe K, Holz M, Schneider E, Rissiek A, Babayan A, Hille C, Pantel K, Krasemann S, Glatzel M, Heiland DH, Flitsch J, ... ... Breakefield XO, et al. Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. Journal of Extracellular Vesicles. 8: 1588555. PMID 30949309 DOI: 10.1080/20013078.2019.1588555 |
0.302 |
|
| 2019 |
Zaborowski MP, Lee K, Na YJ, Sammarco A, Zhang X, Iwanicki M, Cheah PS, Lin HY, Zinter M, Chou CY, Fulci G, Tannous BA, Lai CP, Birrer MJ, Weissleder R, ... ... Breakefield XO, et al. Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Reports. 27: 255-268.e6. PMID 30943406 DOI: 10.1016/J.Celrep.2019.03.003 |
0.327 |
|
| 2018 |
Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenvirons of glioblastoma. Nature Reviews. Neurology. PMID 29985475 DOI: 10.1038/s41582-018-0025-8 |
0.311 |
|
| 2018 |
György B, Lööv C, Zaborowski MP, Takeda S, Kleinstiver BP, Commins C, Kastanenka K, Mu D, Volak A, Giedraitis V, Lannfelt L, Maguire CA, Joung JK, Hyman BT, Breakefield XO, et al. CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. Molecular Therapy. Nucleic Acids. 11: 429-440. PMID 29858078 DOI: 10.1016/J.Omtn.2018.03.007 |
0.634 |
|
| 2018 |
Aneichyk T, Hendriks WT, Yadav R, Shin D, Gao D, Vaine CA, Collins RL, Domingo A, Currall B, Stortchevoi A, Multhaupt-Buell T, Penney EB, Cruz L, Dhakal J, Brand H, ... ... Breakefield XO, et al. Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. Cell. 172: 897-909.e21. PMID 29474918 DOI: 10.1016/J.Cell.2018.02.011 |
0.616 |
|
| 2018 |
György B, Cruz L, Yellen D, Aufiero M, Alland I, Zhang X, Ericsson M, Fraefel C, Li YC, Takeda S, Hyman BT, Breakefield XO. Mutant torsinA in the heterozygous DYT1 state compromises HSV propagation in infected neurons and fibroblasts. Scientific Reports. 8: 2324. PMID 29396398 DOI: 10.1038/S41598-018-19865-2 |
0.36 |
|
| 2018 |
Reátegui E, van der Vos KE, Lai CP, Zeinali M, Atai NA, Aldikacti B, Floyd FP, H Khankhel A, Thapar V, Hochberg FH, Sequist LV, Nahed BV, S Carter B, Toner M, Balaj L, ... ... Breakefield XO, et al. Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nature Communications. 9: 175. PMID 29330365 DOI: 10.1038/S41467-017-02261-1 |
0.317 |
|
| 2018 |
Lee K, Fraser K, Ghaddar B, Yang K, Kim E, Balaj L, Chiocca EA, Breakefield XO, Lee H, Weissleder R. Multiplexed Profiling of Single Extracellular Vesicles. Acs Nano. PMID 29286635 DOI: 10.1021/Acsnano.7B07060 |
0.306 |
|
| 2017 |
Bragg DC, Mangkalaphiban K, Vaine CA, Kulkarni NJ, Shin D, Yadav R, Dhakal J, Ton ML, Cheng A, Russo CT, Ang M, Acuña P, Go C, Franceour TN, Multhaupt-Buell T, ... ... Breakefield XO, et al. Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1. Proceedings of the National Academy of Sciences of the United States of America. PMID 29229810 DOI: 10.1073/Pnas.1712526114 |
0.604 |
|
| 2017 |
György B, Sage C, Indzhykulian AA, Scheffer DI, Brisson AR, Tan S, Wu X, Volak A, Mu D, Tamvakologos PI, Li Y, Fitzpatrick Z, Ericsson M, Breakefield XO, Corey DP, et al. Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28082074 DOI: 10.1016/J.Ymthe.2016.12.010 |
0.66 |
|
| 2016 |
Maas SL, Breakefield XO, Weaver AM. Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends in Cell Biology. PMID 27979573 DOI: 10.1016/J.Tcb.2016.11.003 |
0.301 |
|
| 2016 |
Zappulli V, Friis KP, Fitzpatrick Z, Maguire CA, Breakefield XO. Extracellular vesicles and intercellular communication within the nervous system. The Journal of Clinical Investigation. 126: 1198-207. PMID 27035811 DOI: 10.1172/Jci81134 |
0.62 |
|
| 2016 |
Hall J, Prabhakar S, Balaj L, Lai CP, Cerione RA, Breakefield XO. Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma. Cellular and Molecular Neurobiology. PMID 27017608 DOI: 10.1007/S10571-015-0309-0 |
0.365 |
|
| 2016 |
Zhang X, Abels ER, Redzic JS, Margulis J, Finkbeiner S, Breakefield XO. Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. Cellular and Molecular Neurobiology. PMID 26951563 DOI: 10.1007/S10571-016-0350-7 |
0.364 |
|
| 2016 |
Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. PMID 26905292 DOI: 10.1016/J.Neuropharm.2016.02.013 |
0.639 |
|
| 2016 |
Ito N, Hendriks WT, Dhakal J, Vaine CA, Liu C, Shin D, Shin K, Wakabayashi-Ito N, Dy M, Multhaupt-Buell T, Sharma N, Breakefield XO, Bragg DC. Decreased N-TAF1 expression in X-Linked Dystonia-Parkinsonism patient-specific neural stem cells. Disease Models & Mechanisms. PMID 26769797 DOI: 10.1242/Dmm.022590 |
0.638 |
|
| 2016 |
Gyorgy B, Ingelsson M, Loov C, Takeda S, Lannfelt L, Hyman BT, Breakefield XO. 567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease Molecular Therapy. 24: S226-S227. DOI: 10.1016/S1525-0016(16)33375-5 |
0.328 |
|
| 2015 |
Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. Bioscience. 65: 783-797. PMID 26955082 DOI: 10.1093/biosci/biv084 |
0.325 |
|
| 2015 |
Prabhakar S, Zhang X, Goto J, Han S, Lai C, Bronson R, Sena-Esteves M, Ramesh V, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO. Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiology of Disease. 82: 22-31. PMID 26019056 DOI: 10.1016/J.Nbd.2015.04.018 |
0.384 |
|
| 2015 |
Balaj L, Atai NA, Chen W, Mu D, Tannous BA, Breakefield XO, Skog J, Maguire CA. Heparin affinity purification of extracellular vesicles. Scientific Reports. 5: 10266. PMID 25988257 DOI: 10.1038/Srep10266 |
0.624 |
|
| 2015 |
Lai CP, Kim EY, Badr CE, Weissleder R, Mempel TR, Tannous BA, Breakefield XO. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nature Communications. 6: 7029. PMID 25967391 DOI: 10.1038/Ncomms8029 |
0.317 |
|
| 2015 |
Wakabayashi-Ito N, Ajjuri RR, Henderson BW, Doherty OM, Breakefield XO, O'Donnell JM, Ito N. Mutant human torsinA, responsible for early-onset dystonia, dominantly suppresses GTPCH expression, dopamine levels and locomotion in Drosophila melanogaster. Biology Open. 4: 585-95. PMID 25887123 DOI: 10.1242/bio.201411080 |
0.367 |
|
| 2015 |
Gong Y, Mu D, Prabhakar S, Moser A, Musolino P, Ren J, Breakefield XO, Maguire CA, Eichler FS. Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 824-34. PMID 25592337 DOI: 10.1038/Mt.2015.6 |
0.672 |
|
| 2015 |
Ahmed SG, Hadaegh F, Sena-Esteves M, Maguire CA, Fulci G, Breakefield XO, Brenner GJ. 635. Mechanisms of Caspase-1 Mediated Schwannoma Regression Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34244-7 |
0.657 |
|
| 2015 |
Prabhakar S, Zhang X, Goto J, Sena-Esteves M, Ramesh V, Bronson R, Chen JW, Stemmer-Rachamimov AO, Kwiatkowski DJ, Breakefield XO. 196. AAV-Mediated Gene Replacement Therapy in Mouse Model of Tuberous Sclerosis Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33801-1 |
0.4 |
|
| 2015 |
Gyorgy B, Sage C, Scheffer D, Indzhykulian AA, Mu D, Breakefield XO, Maguire CA, Corey DP. 16. Exosome-Associated AAV as a Novel Platform for Gene Therapy of Hearing Loss Molecular Therapy. 23: S7. DOI: 10.1016/S1525-0016(16)33620-6 |
0.655 |
|
| 2014 |
Rajendran L, Bali J, Barr MM, Court FA, Krämer-Albers EM, Picou F, Raposo G, van der Vos KE, van Niel G, Wang J, Breakefield XO. Emerging roles of extracellular vesicles in the nervous system. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 15482-9. PMID 25392515 DOI: 10.1523/Jneurosci.3258-14.2014 |
0.327 |
|
| 2014 |
Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, et al. Update from the 2013 International Neurofibromatosis Conference. American Journal of Medical Genetics. Part A. 164: 2969-78. PMID 25255738 DOI: 10.1002/Ajmg.A.36754 |
0.303 |
|
| 2014 |
Maguire CA, Ramirez SH, Merkel SF, Sena-Esteves M, Breakefield XO. Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 817-39. PMID 25159276 DOI: 10.1007/S13311-014-0299-5 |
0.661 |
|
| 2014 |
Hettich J, Ryan SD, de Souza ON, Saraiva Macedo Timmers LF, Tsai S, Atai NA, da Hora CC, Zhang X, Kothary R, Snapp E, Ericsson M, Grundmann K, Breakefield XO, Nery FC. Biochemical and cellular analysis of human variants of the DYT1 dystonia protein, TorsinA/TOR1A. Human Mutation. 35: 1101-13. PMID 24930953 DOI: 10.1002/Humu.22602 |
0.317 |
|
| 2014 |
Vader P, Breakefield XO, Wood MJ. Extracellular vesicles: emerging targets for cancer therapy. Trends in Molecular Medicine. 20: 385-93. PMID 24703619 DOI: 10.1016/j.molmed.2014.03.002 |
0.306 |
|
| 2014 |
Lai CP, Mardini O, Ericsson M, Prabhakar S, Maguire CA, Chen JW, Tannous BA, Breakefield XO. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. Acs Nano. 8: 483-94. PMID 24383518 DOI: 10.1021/Nn404945R |
0.628 |
|
| 2014 |
Lai CP, Tannous BA, Breakefield XO. Noninvasive in vivo monitoring of extracellular vesicles. Methods in Molecular Biology (Clifton, N.J.). 1098: 249-58. PMID 24166382 DOI: 10.1007/978-1-62703-718-1_19 |
0.308 |
|
| 2013 |
Armata IA, Balaj L, Kuster JK, Zhang X, Tsai S, Armatas AA, Multhaupt-Buell TJ, Soberman R, Breakefield XO, Ichinose H, Sharma N. Dopa-responsive dystonia: functional analysis of single nucleotide substitutions within the 5' untranslated GCH1 region. Plos One. 8: e76975. PMID 24124602 DOI: 10.1371/Journal.Pone.0076975 |
0.322 |
|
| 2013 |
Atai NA, Balaj L, van Veen H, Breakefield XO, Jarzyna PA, Van Noorden CJ, Skog J, Maguire CA. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. Journal of Neuro-Oncology. 115: 343-51. PMID 24002181 DOI: 10.1007/S11060-013-1235-Y |
0.625 |
|
| 2013 |
Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, Loguidice L, Soto H, Garrett M, Zhu LD, Sivaraman S, Chen C, Wong ET, Carter BS, Hochberg FH, ... Breakefield XO, et al. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Molecular Therapy. Nucleic Acids. 2: e109. PMID 23881452 DOI: 10.1038/Mtna.2013.28 |
0.618 |
|
| 2013 |
Prabhakar S, Goto J, Zhang X, Zuang X, Sena-Esteves M, Bronson R, Brockmann J, Gianni D, Wojtkiewicz GR, Chen JW, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO. Stochastic model of Tsc1 lesions in mouse brain. Plos One. 8: e64224. PMID 23696872 DOI: 10.1371/Journal.Pone.0064224 |
0.343 |
|
| 2013 |
Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, et al. Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 266-8. PMID 23369965 DOI: 10.1038/Mt.2013.4 |
0.333 |
|
| 2013 |
Prabhakar S, Taherian M, Gianni D, Conlon TJ, Fulci G, Brockmann J, Stemmer-Rachamimov A, Sena-Esteves M, Breakefield XO, Brenner GJ. Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Human Gene Therapy. 24: 152-62. PMID 23140466 DOI: 10.1089/Hum.2012.094 |
0.356 |
|
| 2013 |
Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Ströbel T, Breakefield XO, Saydam O. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 101-8. PMID 22910294 DOI: 10.1038/Mt.2012.161 |
0.348 |
|
| 2013 |
Abels ER, van der Vos KE, Breakefield XO. Extracellular Vesicle Transfer of MicroRNA by Tumor Cells Aacr Education Book. 2013: 19-24. DOI: 10.1158/AACR.EDB-13-7859 |
0.302 |
|
| 2012 |
Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, Lee H. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Medicine. 18: 1835-40. PMID 23142818 DOI: 10.1038/Nm.2994 |
0.311 |
|
| 2012 |
Lai CP, Breakefield XO. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Frontiers in Physiology. 3: 228. PMID 22754538 DOI: 10.3389/fphys.2012.00228 |
0.361 |
|
| 2012 |
Atai NA, Ryan SD, Kothary R, Breakefield XO, Nery FC. Untethering the nuclear envelope and cytoskeleton: biologically distinct dystonias arising from a common cellular dysfunction. International Journal of Cell Biology. 2012: 634214. PMID 22611399 DOI: 10.1155/2012/634214 |
0.333 |
|
| 2012 |
Maguire CA, Balaj L, Sivaraman S, Crommentuijn MH, Ericsson M, Mincheva-Nilsson L, Baranov V, Gianni D, Tannous BA, Sena-Esteves M, Breakefield XO, Skog J. Microvesicle-associated AAV vector as a novel gene delivery system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 960-71. PMID 22314290 DOI: 10.1038/Mt.2011.303 |
0.654 |
|
| 2011 |
Carter B, Hochberg F, Breakefield X, Balaj L, Sivaraman S, Curry W, Kalkanis SN, Loguidice L, Russo LM, Noerhelm M, Skog J. Use of exosome analysis to reveal glioma-specific genetic changes in patient serum. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2061. PMID 28019922 DOI: 10.1200/Jco.2011.29.15_Suppl.2061 |
0.35 |
|
| 2011 |
Wakabayashi-Ito N, Doherty OM, Moriyama H, Breakefield XO, Gusella JF, O'Donnell JM, Ito N. Dtorsin, the Drosophila ortholog of the early-onset dystonia TOR1A (DYT1), plays a novel role in dopamine metabolism. Plos One. 6: e26183. PMID 22022556 DOI: 10.1371/journal.pone.0026183 |
0.347 |
|
| 2011 |
Pike LS, Tannous BA, Deliolanis NC, Hsich G, Morse D, Tung CH, Sena-Esteves M, Breakefield XO. Imaging gene delivery in a mouse model of congenital neuronal ceroid lipofuscinosis. Gene Therapy. 18: 1173-8. PMID 21900963 DOI: 10.1038/gt.2011.118 |
0.38 |
|
| 2011 |
Breakefield XO, Frederickson RM, Simpson RJ. Gesicles: Microvesicle "cookies" for transient information transfer between cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1574-6. PMID 21886114 DOI: 10.1038/Mt.2011.169 |
0.334 |
|
| 2011 |
van der Vos KE, Balaj L, Skog J, Breakefield XO. Brain tumor microvesicles: insights into intercellular communication in the nervous system. Cellular and Molecular Neurobiology. 31: 949-59. PMID 21553248 DOI: 10.1007/s10571-011-9697-y |
0.351 |
|
| 2011 |
Bowers WJ, Breakefield XO, Sena-Esteves M. Genetic therapy for the nervous system. Human Molecular Genetics. 20: R28-41. PMID 21429918 DOI: 10.1093/Hmg/Ddr110 |
0.335 |
|
| 2011 |
Bragg DC, Armata IA, Nery FC, Breakefield XO, Sharma N. Molecular pathways in dystonia. Neurobiology of Disease. 42: 136-47. PMID 21134457 DOI: 10.1016/J.Nbd.2010.11.015 |
0.602 |
|
| 2011 |
Saydam O, Ozdener GB, Senol O, Mizrak A, Prabhakar S, Stemmer-Rachamimov AO, Breakefield XO, Brenner GJ. A novel imaging-compatible sciatic nerve schwannoma model. Journal of Neuroscience Methods. 195: 75-7. PMID 21111000 DOI: 10.1016/J.Jneumeth.2010.10.021 |
0.314 |
|
| 2011 |
Noerholm M, Bentink S, Strand M, Ter-Ovanesyan D, Lundin E, Ohlson N, Ottander U, Balaj L, Limperg T, Salehi A, Zhu LD, Hochberg F, Breakefield X, Carter B, Skog J. Abstract C140: RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and ovarian cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C140 |
0.348 |
|
| 2010 |
Breakefield XO, Sena-Esteves M. Healing genes in the nervous system. Neuron. 68: 178-81. PMID 20955923 DOI: 10.1016/j.neuron.2010.10.005 |
0.331 |
|
| 2010 |
Chen P, Burdette AJ, Porter JC, Ricketts JC, Fox SA, Nery FC, Hewett JW, Berkowitz LA, Breakefield XO, Caldwell KA, Caldwell GA. The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Human Molecular Genetics. 19: 3502-15. PMID 20584926 DOI: 10.1093/Hmg/Ddq266 |
0.312 |
|
| 2010 |
Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Therapy. 17: 655-63. PMID 20508670 DOI: 10.1038/Cgt.2010.22 |
0.362 |
|
| 2010 |
Cao S, Hewett JW, Yokoi F, Lu J, Buckley AC, Burdette AJ, Chen P, Nery FC, Li Y, Breakefield XO, Caldwell GA, Caldwell KA. Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. Disease Models & Mechanisms. 3: 386-96. PMID 20223934 DOI: 10.1242/Dmm.003715 |
0.352 |
|
| 2010 |
Prabhakar S, Brenner GJ, Sung B, Messerli SM, Mao J, Sena-Esteves M, Stemmer-Rachamimov A, Tannous B, Breakefield XO. Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter. Cancer Gene Therapy. 17: 266-74. PMID 19834516 DOI: 10.1038/Cgt.2009.71 |
0.313 |
|
| 2009 |
Tannous BA, Chiocca EA, Jacobs AH, Corey DP, Breakefield XO. Tannous et al. Respond. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1311-1312. PMID 28160907 DOI: 10.1038/Mt.2009.166 |
0.307 |
|
| 2009 |
Tannous BA, Christensen AP, Pike L, Wurdinger T, Perry KF, Saydam O, Jacobs AH, García-Añoveros J, Weissleder R, Sena-Esteves M, Corey DP, Breakefield XO. Mutant sodium channel for tumor therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 810-9. PMID 19259066 DOI: 10.1038/Mt.2009.33 |
0.357 |
|
| 2008 |
Schubert M, Breakefield X, Federoff H, Frederickson RM, Lowenstein PR. Gene Delivery to the Nervous System: NINDS Workshop on Gene Delivery to the Nervous System Washington, DC, 12-13 November 2007. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 640-646. PMID 28178462 DOI: 10.1038/Mt.2008.42 |
0.347 |
|
| 2008 |
Maguire CA, Meijer DH, LeRoy SG, Tierney LA, Broekman ML, Costa FF, Breakefield XO, Stemmer-Rachamimov A, Sena-Esteves M. Preventing growth of brain tumors by creating a zone of resistance. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1695-702. PMID 18714312 DOI: 10.1038/Mt.2008.168 |
0.649 |
|
| 2008 |
Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model Journal of Neuroscience. 28: 4406-4413. PMID 18434519 DOI: 10.1523/Jneurosci.0296-08.2008 |
0.375 |
|
| 2008 |
de Oliveira AP, Glauser DL, Laimbacher AS, Strasser R, Schraner EM, Wild P, Ziegler U, Breakefield XO, Ackermann M, Fraefel C. Live visualization of herpes simplex virus type 1 compartment dynamics. Journal of Virology. 82: 4974-90. PMID 18337577 DOI: 10.1128/JVI.02431-07 |
0.305 |
|
| 2008 |
Hewett JW, Nery FC, Niland B, Ge P, Tan P, Hadwiger P, Tannous BA, Sah DW, Breakefield XO. siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells. Human Molecular Genetics. 17: 1436-45. PMID 18258738 DOI: 10.1093/hmg/ddn032 |
0.374 |
|
| 2008 |
Wurdinger T, Badr C, Pike L, de Kleine R, Weissleder R, Breakefield XO, Tannous BA. A secreted luciferase for ex vivo monitoring of in vivo processes. Nature Methods. 5: 171-3. PMID 18204457 DOI: 10.1038/Nmeth.1177 |
0.305 |
|
| 2008 |
Cortés ML, Oehmig A, Saydam O, Sanford JD, Perry KF, Fraefel C, Breakefield XO. Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 81-8. PMID 17998902 DOI: 10.1038/Sj.Mt.6300338 |
0.401 |
|
| 2008 |
Kamm C, Ozelius LJ, Breakefield XO. TorsinA and DYT1 early-onset dystonia Future Neurology. 3: 61-72. DOI: 10.2217/14796708.3.1.61 |
0.354 |
|
| 2007 |
Oehmig A, Cortés ML, Perry KF, Sena-Esteves M, Fraefel C, Breakefield XO. Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector. Gene Therapy. 14: 1078-91. PMID 17460718 DOI: 10.1038/sj.gt.3302960 |
0.33 |
|
| 2007 |
Hewett JW, Tannous B, Niland BP, Nery FC, Zeng J, Li Y, Breakefield XO. Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proceedings of the National Academy of Sciences of the United States of America. 104: 7271-6. PMID 17428918 DOI: 10.1073/Pnas.0701185104 |
0.318 |
|
| 2007 |
Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Therapy. 14: 460-7. PMID 17304235 DOI: 10.1038/Sj.Cgt.7701037 |
0.351 |
|
| 2006 |
Bahn E, Siegert S, Pfander T, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostásy KM. TorsinB expression in the developing human brain. Brain Research. 1116: 112-9. PMID 16938275 DOI: 10.1016/j.brainres.2006.07.102 |
0.374 |
|
| 2006 |
Cortés ML, Oehmig A, Perry KF, Sanford JD, Breakefield XO. Expression of human ATM cDNA in Atm-deficient mouse brain mediated by HSV-1 amplicon vector. Neuroscience. 141: 1247-56. PMID 16809004 DOI: 10.1016/j.neuroscience.2006.05.055 |
0.426 |
|
| 2006 |
Shah K, Breakefield XO. HSV amplicon vectors for cancer therapy. Current Gene Therapy. 6: 361-70. PMID 16787187 DOI: 10.2174/156652306777592063 |
0.409 |
|
| 2006 |
Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO. Metabolic biotinylation of cell surface receptors for in vivo imaging. Nature Methods. 3: 391-6. PMID 16628210 DOI: 10.1038/Nmeth875 |
0.314 |
|
| 2006 |
McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Research. 66: 2509-13. PMID 16510565 DOI: 10.1158/0008-5472.Can-05-2242 |
0.337 |
|
| 2006 |
Messerli SM, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Human Gene Therapy. 17: 20-30. PMID 16409122 DOI: 10.1089/Hum.2006.17.20 |
0.369 |
|
| 2006 |
Hewett JW, Zeng J, Niland BP, Bragg DC, Breakefield XO. Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiology of Disease. 22: 98-111. PMID 16361107 DOI: 10.1016/J.Nbd.2005.10.012 |
0.639 |
|
| 2006 |
Kock N, Allchorne AJ, Sena-Esteves M, Woolf CJ, Breakefield XO. RNAi blocks DYT1 mutant torsinA inclusions in neurons. Neuroscience Letters. 395: 201-5. PMID 16332410 DOI: 10.1016/j.neulet.2005.10.098 |
0.335 |
|
| 2006 |
Messerli S, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Erratum: Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2 (Human Gene Therapy (January 2006) 17, 1 (20-30)) Human Gene Therapy. 17. DOI: 10.1089/Hum.2006.17.796 |
0.333 |
|
| 2006 |
Grandi P, Fernandez J, Szentirmai O, Carter R, Breakefield XO, Sena-Esteves M. 438. Targeting HSV-1 Virions for Specific Binding to Epidermal Growth Factor Receptor-VIII on Tumor Cells Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.504 |
0.379 |
|
| 2006 |
Sanford JD, Oehmig A, Perry KF, Breakefield XO, Cortes ML. 252. Targeted Transgene Integration of the Human ATM cDNA Mediated by HSV/AAV Hybrid Amplicon Vector Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.279 |
0.367 |
|
| 2006 |
Comer LA, Fernandez JL, Camp SM, Tebbets JC, Breakefield XO, Sena-Esteves M. 154. Tetracycline-Inducible HSV Amplicon Vectors with Expanded Range of Gene Expression Regulation Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.177 |
0.396 |
|
| 2006 |
Prabhakar S, Messerli S, Rabkin S, Martuza R, Breakefield XO. 151. Treatment of Experimental Schwannomas with HSV Recombinant and Amplicon Vectors Molecular Therapy. 13: S59. DOI: 10.1016/J.Ymthe.2006.08.174 |
0.383 |
|
| 2006 |
Tannous BA, Perry KF, Sena-Esteves M, Garcias-Anoveros J, Jacobs A, Corey DP, Weissleder R, Breakefield XO. 959. Tumor Therapy Via Vector-Regulated Expression of Mutant Sodium Channel Molecular Therapy. 13: S370. DOI: 10.1016/J.Ymthe.2006.08.1051 |
0.365 |
|
| 2006 |
Badr CE, Zalloua P, Breakefield XO, Tannous BA. 956. Imaging of Radiation-Inducible Promoters Using a Naturally Secreted Luciferase from the Marine Copepod Gaussia princeps Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.1048 |
0.336 |
|
| 2005 |
Brown AB, Mahmood U, Cortes ML, Tang Y, Dai G, Stemmer-Rachamimov A, Prabhakar S, Leishear K, Onda H, Kwiatkowski D, Weissleder R, Breakefield X. Magnetic resonance imaging and characterization of spontaneous lesions in a transgenic mouse model of tuberous sclerosis as a model for endothelial cell-based transgene delivery Human Gene Therapy. 16: 1367-1376. PMID 16390268 DOI: 10.1089/Hum.2005.16.1367 |
0.331 |
|
| 2005 |
Siegert S, Bahn E, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostasy KM. TorsinA expression is detectable in human infants as young as 4 weeks old. Brain Research. Developmental Brain Research. 157: 19-26. PMID 15939081 DOI: 10.1016/j.devbrainres.2005.02.019 |
0.327 |
|
| 2005 |
Sharma N, Baxter MG, Petravicz J, Bragg DC, Schienda A, Standaert DG, Breakefield XO. Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 5351-5. PMID 15930383 DOI: 10.1523/Jneurosci.0855-05.2005 |
0.776 |
|
| 2005 |
Shah K, Tung CH, Breakefield XO, Weissleder R. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 926-31. PMID 15922963 DOI: 10.1016/J.Ymthe.2005.01.017 |
0.304 |
|
| 2005 |
Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 435-43. PMID 15727940 DOI: 10.1016/J.Ymthe.2004.10.016 |
0.385 |
|
| 2005 |
Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, Breakefield XO. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology. 57: 34-41. PMID 15622535 DOI: 10.1002/Ana.20306 |
0.335 |
|
| 2005 |
Wang S, Pike L, Petravicz J, Breakefield XO. 164. Bioluminescence Imaging in the CNS after HSV Amplicon Vector Delivery Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.168 |
0.772 |
|
| 2005 |
Grandi P, McKee TD, Mok W, Fernandez JL, Breakefield XO, Jain RK. 76. New Strategy To Improve Imaging and Retargeting of HSV-1 Vectors Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.054 |
0.306 |
|
| 2005 |
Sharma N, Cristopher Bragg D, Petravicz J, Standaert DG, Breakefield XO. DYT1 transgenic mouse Movement Disorders. 287-292. DOI: 10.1016/B978-012088382-0/50024-4 |
0.735 |
|
| 2004 |
Shah K, Hsich G, Breakefield XO. Neural precursor cells and their role in neuro-oncology. Developmental Neuroscience. 26: 118-30. PMID 15711055 DOI: 10.1159/000082132 |
0.38 |
|
| 2004 |
Oehmig A, Fraefel C, Breakefield XO, Ackermann M. Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus. Current Gene Therapy. 4: 385-408. PMID 15578989 DOI: 10.2174/1566523043346129 |
0.382 |
|
| 2004 |
Bragg DC, Kaufman CA, Kock N, Breakefield XO. Inhibition of N-linked glycosylation prevents inclusion formation by the dystonia-related mutant form of torsinA. Molecular and Cellular Neurosciences. 27: 417-26. PMID 15555920 DOI: 10.1016/J.Mcn.2004.07.009 |
0.616 |
|
| 2004 |
Kamm C, Leung J, Joseph S, Dobyns WB, Brashear A, Breakefield XO, Ozelius LJ. Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 845-7. PMID 15254951 DOI: 10.1002/Mds.20095 |
0.318 |
|
| 2004 |
Hewett JW, Kamm C, Boston H, Beauchamp R, Naismith T, Ozelius L, Hanson PI, Breakefield XO, Ramesh V. TorsinB--perinuclear location and association with torsinA. Journal of Neurochemistry. 89: 1186-94. PMID 15147511 DOI: 10.1111/J.1471-4159.2004.02404.X |
0.376 |
|
| 2004 |
Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Research. 64: 3236-42. PMID 15126365 DOI: 10.1158/0008-5472.Can-03-3516 |
0.35 |
|
| 2004 |
Grandi P, Spear M, Breakefield XO, Wang S. Targeting HSV amplicon vectors. Methods (San Diego, Calif.). 33: 179-86. PMID 15121173 DOI: 10.1016/J.Ymeth.2003.11.007 |
0.375 |
|
| 2004 |
Bragg DC, Camp SM, Kaufman CA, Wilbur JD, Boston H, Schuback DE, Hanson PI, Sena-Esteves M, Breakefield XO. Perinuclear biogenesis of mutant torsin-A inclusions in cultured cells infected with tetracycline-regulated herpes simplex virus type 1 amplicon vectors. Neuroscience. 125: 651-61. PMID 15099679 DOI: 10.1016/J.Neuroscience.2004.01.053 |
0.627 |
|
| 2004 |
Lafreniere RG, MacDonald ML, Dube MP, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio AM, ... ... Breakefield XO, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics. 74: 1064-73. PMID 15060842 DOI: 10.1086/420795 |
0.357 |
|
| 2004 |
Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT, Manservigi R, Breakefield XO. HSV-1 virions engineered for specific binding to cell surface receptors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 419-27. PMID 15006609 DOI: 10.1016/J.Ymthe.2003.12.010 |
0.35 |
|
| 2004 |
Kamm C, Boston H, Hewett J, Wilbur J, Corey DP, Hanson PI, Ramesh V, Breakefield XO. The early onset dystonia protein torsinA interacts with kinesin light chain 1. The Journal of Biological Chemistry. 279: 19882-92. PMID 14970196 DOI: 10.1074/Jbc.M401332200 |
0.331 |
|
| 2004 |
Kabakci K, Hedrich K, Leung JC, Mitterer M, Vieregge P, Lencer R, Hagenah J, Garrels J, Witt K, Klostermann F, Svetel M, Friedman J, Kostic V, Bressman SB, Breakefield XO, et al. Mutations in DYT1: extension of the phenotypic and mutational spectrum. Neurology. 62: 395-400. PMID 14872019 DOI: 10.1212/01.WNL.0000113024.84178.F7 |
0.323 |
|
| 2004 |
Shah K, Tung CH, Chang CH, Slootweg E, O'Loughlin T, Breakefield XO, Weissleder R. In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Research. 64: 273-8. PMID 14729634 DOI: 10.1158/0008-5472.Can-03-1123 |
0.302 |
|
| 2004 |
Bragg DC, Slater DJ, Breakefield XO. TorsinA and early-onset torsion dystonia. Advances in Neurology. 94: 87-93. PMID 14509659 |
0.506 |
|
| 2004 |
Tang Y, Shah K, Messerli SM, Snyder E, Breakefield X, Weissleder R. In vivo tracking of neural progenitor cell migration to glioblastomas. Human Gene Therapy. 14: 1247-54. PMID 12952596 DOI: 10.1089/104303403767740786 |
0.353 |
|
| 2004 |
Wang S, Petravicz J, Breakefield XO. 64. Bioluminescence Imaging of Regulated Gene Expression Using HSV-1 Amplicon Vectors in Rodent Brain Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.082 |
0.779 |
|
| 2004 |
Cole C, Diaz RM, Forshaw M, Kottke T, Thompson J, Gough M, Breakefield X, Sena-Esteves M, Qiao J, Vile RG. 23. T Cell Carriers for Gene Delivery to Tumors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.046 |
0.37 |
|
| 2003 |
Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO, Aboody KS. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Human Gene Therapy. 14: 1777-85. PMID 14670128 DOI: 10.1089/104303403322611782 |
0.32 |
|
| 2003 |
Yoshimura S, Teramoto T, Whalen MJ, Irizarry MC, Takagi Y, Qiu J, Harada J, Waeber C, Breakefield XO, Moskowitz MA. FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice. The Journal of Clinical Investigation. 112: 1202-10. PMID 14561705 DOI: 10.1172/JCI16618 |
0.301 |
|
| 2003 |
Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene. 22: 6865-72. PMID 14534533 DOI: 10.1038/Sj.Onc.1206748 |
0.353 |
|
| 2003 |
Augood SJ, Keller-McGandy CE, Siriani A, Hewett J, Ramesh V, Sapp E, DiFiglia M, Breakefield XO, Standaert DG. Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Research. 986: 12-21. PMID 12965225 DOI: 10.1016/S0006-8993(03)03164-0 |
0.321 |
|
| 2003 |
Bakowska JC, Di Maria MV, Camp SM, Wang Y, Allen PD, Breakefield XO. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. Gene Therapy. 10: 1691-702. PMID 12923568 DOI: 10.1038/sj.gt.3302061 |
0.354 |
|
| 2003 |
Cortés ML, Bakkenist CJ, Di Maria MV, Kastan MB, Breakefield XO. HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Gene Therapy. 10: 1321-7. PMID 12883528 DOI: 10.1038/Sj.Gt.3301996 |
0.377 |
|
| 2003 |
Hampl JA, Camp SM, Mydlarz WK, Hampl M, Ichikawa T, Chiocca EA, Louis DN, Sena-Esteves M, Breakefield XO. Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Human Gene Therapy. 14: 611-26. PMID 12804144 DOI: 10.1089/104303403321618137 |
0.391 |
|
| 2003 |
Wang S, Petravicz J, Breakefield XO. Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 7: 790-800. PMID 12788653 DOI: 10.1016/S1525-0016(03)00094-7 |
0.787 |
|
| 2003 |
Davidson BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nature Reviews. Neuroscience. 4: 353-64. PMID 12728263 DOI: 10.1038/Nrn1104 |
0.417 |
|
| 2003 |
Hewett J, Ziefer P, Bergeron D, Naismith T, Boston H, Slater D, Wilbur J, Schuback D, Kamm C, Smith N, Camp S, Ozelius LJ, Ramesh V, Hanson PI, Breakefield XO. TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress. Journal of Neuroscience Research. 72: 158-68. PMID 12671990 DOI: 10.1002/Jnr.10567 |
0.306 |
|
| 2003 |
Rostasy K, Augood SJ, Hewett JW, Leung JC, Sasaki H, Ozelius LJ, Ramesh V, Standaert DG, Breakefield XO, Hedreen JC. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiology of Disease. 12: 11-24. PMID 12609485 DOI: 10.1016/S0969-9961(02)00010-4 |
0.338 |
|
| 2003 |
Spear MA, Schuback D, Miyata K, Grandi P, Sun F, Yoo L, Nguyen A, Brandt CR, Breakefield XO. HSV-1 amplicon peptide display vector. Journal of Virological Methods. 107: 71-9. PMID 12445940 DOI: 10.1016/S0166-0934(02)00193-3 |
0.357 |
|
| 2002 |
Lam P, Hui KM, Wang Y, Allen PD, Louis DN, Yuan CJ, Breakefield XO. Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors. Human Gene Therapy. 13: 2147-59. PMID 12542846 DOI: 10.1089/104303402320987842 |
0.403 |
|
| 2002 |
Sandler VM, Wang S, Angelo K, Lo HG, Breakefield XO, Clapham DE. Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. Journal of Neuroscience Methods. 121: 211-9. PMID 12468010 DOI: 10.1016/S0165-0270(02)00262-5 |
0.352 |
|
| 2002 |
Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO. Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia (New York, N.Y.). 4: 501-9. PMID 12407444 DOI: 10.1038/Sj.Neo.7900265 |
0.346 |
|
| 2002 |
Doheny D, Danisi F, Smith C, Morrison C, Velickovic M, De Leon D, Bressman SB, Leung J, Ozelius L, Klein C, Breakefield XO, Brin MF, Silverman JM. Clinical findings of a myoclonus-dystonia family with two distinct mutations. Neurology. 59: 1244-6. PMID 12391355 DOI: 10.1212/Wnl.59.8.1244 |
0.319 |
|
| 2002 |
Sena-Esteves M, Hampl JA, Camp SM, Breakefield XO. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors. The Journal of Gene Medicine. 4: 229-39. PMID 12112640 DOI: 10.1002/jgm.276 |
0.395 |
|
| 2002 |
Wang Y, Camp SM, Niwano M, Shen X, Bakowska JC, Breakefield XO, Allen PD. Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. Journal of Virology. 76: 7150-62. PMID 12072515 DOI: 10.1128/JVI.76.14.7150-7162.2002 |
0.385 |
|
| 2002 |
Ziefer P, Leung J, Razzano T, Shalish C, LeDoux MS, Lorden JF, Ozelius L, Breakefield XO, Standaert DG, Augood SJ. Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat. Brain Research. Molecular Brain Research. 101: 132-5. PMID 12007841 DOI: 10.1016/S0169-328X(02)00176-6 |
0.318 |
|
| 2002 |
Costantini LC, Fraefel C, Breakefield XO, Isacson O. Herpes simplex virus/adeno-associated virus hybrid vectors for gene transfer to neurons. Preparation and use. Methods in Molecular Medicine. 69: 461-79. PMID 11987795 DOI: 10.1385/1-59259-141-8:461 |
0.322 |
|
| 2002 |
Hsich G, Sena-Esteves M, Breakefield XO. Critical issues in gene therapy for neurologic disease. Human Gene Therapy. 13: 579-604. PMID 11916483 DOI: 10.1089/10430340252837198 |
0.376 |
|
| 2002 |
Wang Y, Mukherjee S, Fraefel C, Breakefield XO, Allen PD. Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. Human Gene Therapy. 13: 261-73. PMID 11812282 DOI: 10.1089/10430340252769789 |
0.371 |
|
| 2001 |
Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, Kamm C, DeLeon D, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, ... ... Breakefield XO, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics. 3: 133-43. PMID 11523564 DOI: 10.1007/s100480100111 |
0.321 |
|
| 2001 |
Spear MA, Breakefield XO, Beltzer J, Schuback D, Weissleder R, Pardo FS, Ladner R. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Therapy. 8: 506-11. PMID 11498772 DOI: 10.1038/Sj.Cgt.7700334 |
0.339 |
|
| 2001 |
Breakefield XO, Kamm C, Hanson PI. TorsinA: movement at many levels. Neuron. 31: 9-12. PMID 11498045 DOI: 10.1016/S0896-6273(01)00350-6 |
0.305 |
|
| 2001 |
Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O, Schwinger E, Vieregge P, Lang AE, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Human Molecular Genetics. 10: 1649-56. PMID 11487568 DOI: 10.1093/Hmg/10.16.1649 |
0.33 |
|
| 2001 |
Yoshimura S, Takagi Y, Harada J, Teramoto T, Thomas SS, Waeber C, Bakowska JC, Breakefield XO, Moskowitz MA. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proceedings of the National Academy of Sciences of the United States of America. 98: 5874-9. PMID 11320217 DOI: 10.1073/pnas.101034998 |
0.321 |
|
| 2001 |
Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Molecular Therapy : the Journal of the American Society of Gene Therapy. 3: 591-601. PMID 11319922 DOI: 10.1006/Mthe.2001.0294 |
0.321 |
|
| 2001 |
Lam PY, Breakefield XO. Potential of gene therapy for brain tumors. Human Molecular Genetics. 10: 777-87. PMID 11257112 DOI: 10.1093/Hmg/10.7.777 |
0.376 |
|
| 2000 |
Herrlinger U, Jacobs A, Aghi M, Schuback DE, Breakefield XO. HSV-1 Vectors for Gene Therapy of Experimental CNS Tumors. Methods in Molecular Medicine. 35: 287-312. PMID 21390812 DOI: 10.1385/1-59259-086-1:287 |
0.397 |
|
| 2000 |
Lam PY, Breakefield XO. Hybrid vector designs to control the delivery, fate and expression of transgenes. The Journal of Gene Medicine. 2: 395-408. PMID 11199260 DOI: 10.1002/1521-2254(200011/12)2:6<395::AID-JGM146>3.0.CO;2-K |
0.39 |
|
| 2000 |
Friedman JR, Klein C, Leung J, Woodward H, Ozelius LJ, Breakefield XO, Charness ME. The GAG deletion of the DYT1 gene is infrequent in musicians with focal dystonia. Neurology. 55: 1417-8. PMID 11087801 DOI: 10.1212/Wnl.55.9.1417 |
0.337 |
|
| 2000 |
Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Therapy. 7: 1648-55. PMID 11083473 DOI: 10.1038/Sj.Gt.3301272 |
0.329 |
|
| 2000 |
Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proceedings of the National Academy of Sciences of the United States of America. 97: 12846-51. PMID 11070094 DOI: 10.1073/pnas.97.23.12846 |
0.346 |
|
| 2000 |
Fraefel C, Jacoby DR, Breakefield XO. Herpes simplex virus type 1-based amplicon vector systems. Advances in Virus Research. 55: 425-51. PMID 11050950 DOI: 10.1016/S0065-3527(00)55011-8 |
0.381 |
|
| 2000 |
Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, Snyder EY, Breakefield XO. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 1: 347-57. PMID 10933953 DOI: 10.1006/mthe.2000.0046 |
0.379 |
|
| 2000 |
Klein C, Kann M, Kis B, Pramstaller PP, Breakefield XO, Ozelius LJ, Vieregge P. [Genetics of dystonia]. Der Nervenarzt. 71: 431-41. PMID 10919137 DOI: 10.1007/s001150050604 |
0.333 |
|
| 2000 |
Herrlinger U, Jacobs A, Quinones A, Woiciechowsky C, Sena-Esteves M, Rainov NG, Fraefel C, Breakefield XO. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Human Gene Therapy. 11: 1429-38. PMID 10910140 DOI: 10.1089/10430340050057503 |
0.359 |
|
| 2000 |
Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. The Journal of Gene Medicine. 2: 148-64. PMID 10894261 DOI: 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q |
0.371 |
|
| 2000 |
Klein C, Pramstaller PP, Kis B, Page CC, Kann M, Leung J, Woodward H, Castellan CC, Scherer M, Vieregge P, Breakefield XO, Kramer PL, Ozelius LJ. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Annals of Neurology. 48: 65-71. PMID 10894217 DOI: 10.1002/1531-8249(200007)48:1<65::AID-ANA10>3.0.CO;2-L |
0.322 |
|
| 2000 |
Hewett J, Gonzalez-Agosti C, Slater D, Ziefer P, Li S, Bergeron D, Jacoby DJ, Ozelius LJ, Ramesh V, Breakefield XO. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Human Molecular Genetics. 9: 1403-13. PMID 10814722 DOI: 10.1093/Hmg/9.9.1403 |
0.355 |
|
| 2000 |
Sena-Esteves M, Camp SM, Alroy J, Breakefield XO, Kaye EM. Correction of acid beta-galactosidase deficiency in GM1 gangliosidosis human fibroblasts by retrovirus vector-mediated gene transfer: higher efficiency of release and cross-correction by the murine enzyme. Human Gene Therapy. 11: 715-27. PMID 10757351 DOI: 10.1089/10430340050015617 |
0.342 |
|
| 2000 |
Costantini LC, Bakowska JC, Breakefield XO, Isacson O. Gene therapy in the CNS. Gene Therapy. 7: 93-109. PMID 10673714 DOI: 10.1038/sj.gt.3301119 |
0.385 |
|
| 1999 |
Klein C, Breakefield XO, Ozelius LJ. Genetics of primary dystonia. Seminars in Neurology. 19: 271-80. PMID 12194383 DOI: 10.1055/s-2008-1040843 |
0.341 |
|
| 1999 |
Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia (New York, N.Y.). 1: 402-16. PMID 10933055 DOI: 10.1038/Sj.Neo.7900056 |
0.4 |
|
| 1999 |
Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis. Neoplasia (New York, N.Y.). 1: 387-401. PMID 10933054 DOI: 10.1038/Sj.Neo.7900055 |
0.408 |
|
| 1999 |
Jacobs A, Dubrovin M, Hewett J, Sena-Esteves M, Tan CW, Slack M, Sadelain M, Breakefield XO, Tjuvajev JG. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia (New York, N.Y.). 1: 154-61. PMID 10933050 DOI: 10.1038/Sj.Neo.7900007 |
0.388 |
|
| 1999 |
Pechan PA, Herrlinger U, Aghi M, Jacobs A, Breakefield XO. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. The Journal of Gene Medicine. 1: 176-85. PMID 10738566 DOI: 10.1002/(SICI)1521-2254(199905/06)1:3<176::AID-JGM35>3.0.CO;2-T |
0.39 |
|
| 1999 |
Ozelius LJ, Page CE, Klein C, Hewett JW, Mineta M, Leung J, Shalish C, Bressman SB, de Leon D, Brin MF, Fahn S, Corey DP, Breakefield XO. The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics. 62: 377-84. PMID 10644435 DOI: 10.1006/geno.1999.6039 |
0.346 |
|
| 1999 |
Aghi M, Kramm CM, Breakefield XO. RESPONSE: Re: Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo. Journal of the National Cancer Institute. 91: 2048-2049. PMID 10580034 DOI: 10.1093/Jnci/91.23.2048 |
0.301 |
|
| 1999 |
Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, Breakefield XO. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. Journal of Virology. 73: 10426-39. PMID 10559361 DOI: 10.1128/Jvi.73.12.10426-10439.1999 |
0.385 |
|
| 1999 |
Rainov NG, Ikeda K, Qureshi N, Grover S, Barnett FH, Herrlinger U, Quinones A, Chiocca EA, Breakefield XO. Intra-arterial virus and nonvirus vector-mediated gene transfer to experimental rat brain tumors. Frontiers of Radiation Therapy and Oncology. 33: 227-40. PMID 10549492 DOI: 10.1159/000061238 |
0.333 |
|
| 1999 |
Costantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Human Gene Therapy. 10: 2481-94. PMID 10543613 DOI: 10.1089/10430349950016825 |
0.386 |
|
| 1999 |
Derby ML, Sena-Esteves M, Breakefield XO, Corey DP. Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. Hearing Research. 134: 1-8. PMID 10452370 DOI: 10.1016/S0378-5955(99)00045-3 |
0.397 |
|
| 1999 |
Barnett FH, Rainov NG, Ikeda K, Schuback DE, Elliott P, Kramm CM, Chase M, Qureshi NH, Harsh G, Chiocca EA, Breakefield XO. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Therapy. 6: 14-20. PMID 10078959 DOI: 10.1038/Sj.Cgt.7700003 |
0.379 |
|
| 1999 |
Schuback DE, Mulligan EL, Sims KB, Tivol EA, Greenberg BD, Chang SF, Yang SL, Mau YC, Shen CY, Ho MS, Yang NH, Butler MG, Fink S, Schwartz CE, Berlin F, ... Breakefield XO, et al. Screen for MAOA mutations in target human groups. American Journal of Medical Genetics. 88: 25-8. PMID 10050962 DOI: 10.1002/(Sici)1096-8628(19990205)88:1<25::Aid-Ajmg4>3.0.Co;2-E |
0.305 |
|
| 1998 |
Rainov NG, Sena-Esteves M, Fraefel C, Dobberstein KU, Chiocca EA, Breakefield XO. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Advances in Experimental Medicine and Biology. 451: 393-403. PMID 10026902 DOI: 10.1007/978-1-4615-5357-1_61 |
0.421 |
|
| 1998 |
Klein C, Pramstaller PP, Castellan CC, Breakefield XO, Kramer PL, Ozelius LJ. Clinical and genetic evaluation of a family with a mixed dystonia phenotype from South Tyrol. Annals of Neurology. 44: 394-8. PMID 9749609 DOI: 10.1002/ana.410440318 |
0.315 |
|
| 1998 |
Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, Pechan PA, Barth RF, Finkelstein D, Chiocca EA, Louis DN, Breakefield XO. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Therapy. 5: 809-19. PMID 9747461 DOI: 10.1038/Sj.Gt.3300643 |
0.372 |
|
| 1998 |
Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, Hilton J, Chiocca EA, Breakefield XO. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Human Gene Therapy. 9: 1261-73. PMID 9650611 DOI: 10.1089/Hum.1998.9.9-1261 |
0.419 |
|
| 1998 |
Klein C, Brin MF, de Leon D, Limborska SA, Ivanova-Smolenskaya IA, Bressman SB, Friedman A, Markova ED, Risch NJ, Breakefield XO, Ozelius LJ. De novo mutations (GAG deletion) in the DYT1 gene in two non-Jewish patients with early-onset dystonia. Human Molecular Genetics. 7: 1133-6. PMID 9618171 DOI: 10.1093/hmg/7.7.1133 |
0.312 |
|
| 1998 |
Bagley J, Aboody-Guterman K, Breakefield X, Iacomini J. Long-term expression of the gene encoding green fluorescent protein in murine hematopoietic cells using retroviral gene transfer. Transplantation. 65: 1233-1240. PMID 9603173 DOI: 10.1097/00007890-199805150-00015 |
0.36 |
|
| 1998 |
Augood SJ, Penney JB, Friberg IK, Breakefield XO, Young AB, Ozelius LJ, Standaert DG. Expression of the early-onset torsion dystonia gene (DYT1) in human brain. Annals of Neurology. 43: 669-73. PMID 9585364 DOI: 10.1002/ana.410430518 |
0.385 |
|
| 1998 |
Spear MA, Herrlinger U, Rainov N, Pechan P, Weissleder R, Breakefield XO. Targeting gene therapy vectors to CNS malignancies. Journal of Neurovirology. 4: 133-47. PMID 9584951 DOI: 10.3109/13550289809114514 |
0.371 |
|
| 1998 |
Murphy DL, Sims K, Eisenhofer G, Greenberg BD, George T, Berlin F, Zametkin A, Ernst M, Breakefield XO. Are MAO-A deficiency states in the general population and in putative high-risk populations highly uncommon? Journal of Neural Transmission. Supplementum. 52: 29-38. PMID 9564605 DOI: 10.1007/978-3-7091-6499-0_4 |
0.3 |
|
| 1998 |
Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. Journal of the National Cancer Institute. 90: 370-80. PMID 9498487 DOI: 10.1093/Jnci/90.5.370 |
0.333 |
|
| 1998 |
Schellingerhout D, Bogdanov AJ, Marecos E, Spear M, Breakefield X, Weissleder R. Corrigendum: Mapping the in vivo distribution of Herpes simplex virions (Human Gene Therapy (1998) 9, 11) Human Gene Therapy. 9. DOI: 10.1089/10430349850019490 |
0.301 |
|
| 1997 |
Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, Majzoub JA. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Molecular Medicine (Cambridge, Mass.). 3: 813-25. PMID 9440115 DOI: 10.1007/Bf03401718 |
0.377 |
|
| 1997 |
Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefield XO. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Human Gene Therapy. 8: 2057-68. PMID 9414254 DOI: 10.1089/hum.1997.8.17-2057 |
0.369 |
|
| 1997 |
Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, de Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nature Genetics. 17: 40-8. PMID 9288096 DOI: 10.1038/ng0997-40 |
0.333 |
|
| 1997 |
Paulus W, Baur I, Oberer DM, Breakefield XO, Reeves SA. Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. Journal of Neurosurgery. 87: 89-95. PMID 9202271 DOI: 10.3171/jns.1997.87.1.0089 |
0.391 |
|
| 1997 |
Ozelius LJ, Hewett J, Kramer P, Bressman SB, Shalish C, de Leon D, Rutter M, Risch N, Brin MF, Markova ED, Limborska SA, Ivanova-Smolenskaya IA, McCormick MK, Fahn S, Buckler AJ, ... ... Breakefield XO, et al. Fine localization of the torsion dystonia gene (DYT1) on human chromosome 9q34: YAC map and linkage disequilibrium. Genome Research. 7: 483-94. PMID 9149944 DOI: 10.1101/Gr.7.5.483 |
0.321 |
|
| 1997 |
Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, Breakefield XO. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Human Gene Therapy. 8: 359-70. PMID 9048203 DOI: 10.1089/Hum.1997.8.3-359 |
0.391 |
|
| 1997 |
Zimmer C, Wright SC, Engelhardt RT, Johnson GA, Kramm C, Breakefield XO, Weissleder R. Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface. Experimental Neurology. 143: 61-9. PMID 9000446 DOI: 10.1006/Exnr.1996.6350 |
0.325 |
|
| 1996 |
Pechan PA, Fotaki M, Thompson RL, Dunn R, Chase M, Chiocca EA, Breakefield XO. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Human Gene Therapy. 7: 2003-13. PMID 8930661 DOI: 10.1089/Hum.1996.7.16-2003 |
0.389 |
|
| 1996 |
Kramm CM, Rainov NG, Sena-Esteves M, Barnett FH, Chase M, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Human Gene Therapy. 7: 1989-94. PMID 8930659 DOI: 10.1089/Hum.1996.7.16-1989 |
0.371 |
|
| 1996 |
Battinelli EM, Boyd Y, Craig IW, Breakefield XO, Chen ZY. Characterization and mapping of the mouse NDP (Norrie disease) locus (Ndp). Mammalian Genome : Official Journal of the International Mammalian Genome Society. 7: 93-7. PMID 8835523 DOI: 10.1007/S003359900026 |
0.369 |
|
| 1996 |
Kramm CM, Rainov NG, Sena-Esteves M, Chase M, Pechan PA, Chiocca EA, Breakefield XO. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Human Gene Therapy. 7: 291-300. PMID 8835217 DOI: 10.1089/Hum.1996.7.3-291 |
0.401 |
|
| 1996 |
Gasser T, Bove CM, Ozelius LJ, Hallett M, Charness ME, Hochberg FH, Breakefield XO. Haplotype analysis at the DYT1 locus in Ashkenazi Jewish patients with occupational hand dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 163-6. PMID 8684386 DOI: 10.1002/mds.870110208 |
0.312 |
|
| 1996 |
Tivol EA, Shalish C, Schuback DE, Hsu YP, Breakefield XO. Mutational analysis of the human MAOA gene. American Journal of Medical Genetics. 67: 92-7. PMID 8678123 DOI: 10.1002/(SICI)1096-8628(19960216)67:1<92::AID-AJMG16>3.0.CO;2-K |
0.334 |
|
| 1996 |
Paulus W, Baur I, Boyce FM, Breakefield XO, Reeves SA. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. Journal of Virology. 70: 62-7. PMID 8523582 DOI: 10.1128/Jvi.70.1.62-67.1996 |
0.407 |
|
| 1995 |
Smith F, Jacoby D, Breakefield XO. Virus vectors for gene delivery to the nervous system. Restorative Neurology and Neuroscience. 8: 21-34. PMID 21551801 DOI: 10.3233/RNN-1995-81207 |
0.392 |
|
| 1995 |
Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan PA, Paulus W, Chiocca EA, Breakefield XO. Gene therapy for brain tumors. Brain Pathology (Zurich, Switzerland). 5: 345-81. PMID 8974620 DOI: 10.1111/J.1750-3639.1995.Tb00615.X |
0.367 |
|
| 1995 |
Rainov NG, Zimmer C, Chase M, Kramm CM, Chiocca EA, Weissleder R, Breakefield XO. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Human Gene Therapy. 6: 1543-52. PMID 8664379 DOI: 10.1089/Hum.1995.6.12-1543 |
0.352 |
|
| 1995 |
Tamiya T, Wei MX, Chase M, Ono Y, Lee F, Breakefield XO, Chiocca EA. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Therapy. 2: 531-8. PMID 8593603 |
0.308 |
|
| 1995 |
Yoshimoto Y, Lin Q, Collier TJ, Frim DM, Breakefield XO, Bohn MC. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Research. 691: 25-36. PMID 8590062 DOI: 10.1016/0006-8993(95)00596-I |
0.308 |
|
| 1995 |
Chen ZY, Denney RM, Breakefield XO. Norrie disease and MAO genes: nearest neighbors. Human Molecular Genetics. 4: 1729-37. PMID 8541872 DOI: 10.1093/Hmg/4.Suppl_1.1729 |
0.348 |
|
| 1995 |
Slaugenhaupt SA, Blumenfeld A, Liebert CB, Mull J, Lucente DE, Monahan M, Breakefield XO, Maayan C, Parada L, Axelrod FB. The human gene for neurotrophic tyrosine kinase receptor type 2 (NTRK2) is located on chromosome 9 but is not the familial dysautonomia gene. Genomics. 25: 730-2. PMID 7759111 DOI: 10.1016/0888-7543(95)80019-I |
0.336 |
|
| 1995 |
Schuback DE, Chen ZY, Craig IW, Breakefield XO, Sims KB. Mutations in the Norrie disease gene. Human Mutation. 5: 285-92. PMID 7627181 DOI: 10.1002/humu.1380050403 |
0.307 |
|
| 1995 |
Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, Neuwelt EA. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proceedings of the National Academy of Sciences of the United States of America. 92: 9829-33. PMID 7568227 DOI: 10.1073/Pnas.92.21.9829 |
0.356 |
|
| 1995 |
Blumenfeld A, Lucente DE, Trofatter JA, Lerner T, Slaugenhaupt SA, Liebert CB, Monahan M, Haines JL, Gusella JF, Breakefield XO, Parysek LM. Peripherin gene is linked to keratin 18 gene on human chromosome 12. Somatic Cell and Molecular Genetics. 21: 83-8. PMID 7541564 DOI: 10.1007/BF02255825 |
0.334 |
|
| 1994 |
Boviatsis EJ, Chase M, Wei MX, Tamiya T, Hurford RK, Kowall NW, Tepper RI, Breakefield XO, Chiocca EA. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Human Gene Therapy. 5: 183-91. PMID 8186298 DOI: 10.1089/Hum.1994.5.2-183 |
0.401 |
|
| 1994 |
Davar G, Kramer MF, Garber D, Roca AL, Andersen JK, Bebrin W, Coen DM, Kosz-Vnenchak M, Knipe DM, Breakefield XO. Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. The Journal of Comparative Neurology. 339: 3-11. PMID 8106660 DOI: 10.1002/Cne.903390103 |
0.337 |
|
| 1994 |
Castillo B, del Cerro M, Breakefield XO, Frim DM, Barnstable CJ, Dean DO, Bohn MC. Retinal ganglion cell survival is promoted by genetically modified astrocytes designed to secrete brain-derived neurotrophic factor (BDNF). Brain Research. 647: 30-6. PMID 8069702 DOI: 10.1016/0006-8993(94)91395-1 |
0.303 |
|
| 1994 |
Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TK, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, Chiocca EA. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Human Gene Therapy. 5: 969-78. PMID 7948146 DOI: 10.1089/Hum.1994.5.8-969 |
0.371 |
|
| 1994 |
Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, Chiocca EA. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Therapy. 1: 323-31. PMID 7584098 |
0.625 |
|
| 1993 |
Breakefield XO. Gene delivery into the brain using virus vectors. Nature Genetics. 3: 187-9. PMID 8485570 DOI: 10.1038/ng0393-187 |
0.347 |
|
| 1993 |
Hoffman D, Breakefield XO, Short MP, Aebischer P. Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Experimental Neurology. 122: 100-6. PMID 8339781 DOI: 10.1006/exnr.1993.1111 |
0.308 |
|
| 1993 |
Chen ZY, Battinelli EM, Hendriks RW, Powell JF, Middleton-Price H, Sims KB, Breakefield XO, Craig IW. Norrie disease gene: characterization of deletions and possible function. Genomics. 16: 533-5. PMID 8314592 DOI: 10.1006/geno.1993.1224 |
0.387 |
|
| 1993 |
Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, Walsh LE, Kasarskis EJ, Butler IJ, Breakefield XO. Rapid-onset dystonia-parkinsonism. Neurology. 43: 2596-602. PMID 8255463 DOI: 10.1212/Wnl.43.12.2596 |
0.318 |
|
| 1993 |
Andersen JK, Frim DM, Isacson O, Breakefield XO. Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cellular and Molecular Neurobiology. 13: 503-15. PMID 8111822 DOI: 10.1007/Bf00711459 |
0.385 |
|
| 1993 |
Blumenfeld A, Slaugenhaupt SA, Axelrod FB, Lucente DE, Maayan C, Liebert CB, Ozelius LJ, Trofatter JA, Haines JL, Breakefield XO. Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. Nature Genetics. 4: 160-4. PMID 8102296 DOI: 10.1038/ng0693-160 |
0.309 |
|
| 1993 |
Frim DM, Short MP, Breakefield XO, Isacson O. Biological Gene-Product Delivery to the Brain: A Protocol for Retroviral Gene Transfer into Cultured Cells and Intracerebral Transplantation Neuroprotocols. 3: 63-68. DOI: 10.1006/Ncmn.1993.1038 |
0.375 |
|
| 1992 |
Rosenberg WS, Breakefield XO, DeAntonio C, Isacson O. Authentic and artifactual detection of the E. coli lacZ gene product in the rat brain by histochemical methods. Brain Research. Molecular Brain Research. 16: 311-5. PMID 1337940 DOI: 10.1016/0169-328X(92)90240-C |
0.349 |
|
| 1992 |
Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. Journal of Neuroscience Research. 33: 493-503. PMID 1335091 DOI: 10.1002/jnr.490330316 |
0.399 |
|
| 1992 |
Andersen JK, Garber DA, Meaney CA, Breakefield XO. Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Human Gene Therapy. 3: 487-99. PMID 1329993 DOI: 10.1089/hum.1992.3.5-487 |
0.366 |
|
| 1992 |
Huang Q, Vonsattel JP, Schaffer PA, Martuza RL, Breakefield XO, DiFiglia M. Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Experimental Neurology. 115: 303-16. PMID 1311266 DOI: 10.1016/0014-4886(92)90196-W |
0.352 |
|
| 1992 |
Chen ZY, Sims KB, Coleman M, Donnai D, Monaco A, Breakefield XO, Davies KE, Craig IW. Characterization of a YAC containing part or all of the Norrie disease locus. Human Molecular Genetics. 1: 161-4. PMID 1303171 DOI: 10.1093/Hmg/1.3.161 |
0.303 |
|
| 1992 |
Sims KB, Lebo RV, Benson G, Shalish C, Schuback D, Chen ZY, Bruns G, Craig IW, Golbus MS, Breakefield XO. The Norrie disease gene maps to a 150 kb region on chromosome Xp11.3. Human Molecular Genetics. 1: 83-9. PMID 1301161 DOI: 10.1093/Hmg/1.2.83 |
0.34 |
|
| 1991 |
Chen ZY, Hotamisligil GS, Huang JK, Wen L, Ezzeddine D, Aydin-Muderrisoglu N, Powell JF, Huang RH, Breakefield XO, Craig I. Structure of the human gene for monoamine oxidase type A. Nucleic Acids Research. 19: 4537-41. PMID 1886775 DOI: 10.1093/Nar/19.16.4537 |
0.338 |
|
| 1991 |
Schuback D, Kramer P, Ozelius L, Holmgren G, Forsgren L, Kyllerman M, Wahlström J, Craft CM, Nygaard T, Brin M, de Leon D, Bressman S, Moskowitz CB, Burke RE, Sanner G, ... ... Breakefield XO, et al. Dopamine beta-hydroxylase gene excluded in four subtypes of hereditary dystonia Human Genetics. 87: 311-316. PMID 1677923 DOI: 10.1007/BF00200910 |
0.335 |
|
| 1991 |
Cunningham LA, Short MP, Vielkind U, Breakefield XO, Bohn MC. Survival and differentiation within the adult mouse striatum of grafted rat pheochromocytoma cells (PC12) genetically modified to express recombinant beta-NGF. Experimental Neurology. 112: 174-82. PMID 1674694 DOI: 10.1016/0014-4886(91)90067-M |
0.332 |
|
| 1990 |
Diergaarde PJ, Wieringa B, Bleeker-Wagemakers EM, Sims KB, Breakefield XO, Ropers HH. Physical fine-mapping of a deletion spanning the Norrie gene. Human Genetics. 84: 22-6. PMID 2606473 DOI: 10.1007/BF00210665 |
0.318 |
|
| 1990 |
Ozelius L, Gusella JF, Breakefield XO. MspI RFLP for human MAOA gene. Nucleic Acids Research. 17: 10516. PMID 2481273 DOI: 10.1093/NAR/17.24.10516 |
0.313 |
|
| 1990 |
Short MP, Choi BC, Lee JK, Malick A, Breakefield XO, Martuza RL. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. Journal of Neuroscience Research. 27: 427-39. PMID 2129047 DOI: 10.1002/Jnr.490270322 |
0.378 |
|
| 1990 |
Short MP, Rosenberg MB, Ezzedine ZD, Gage FH, Friedmann T, Breakefield XO. Autocrine differentiation of PC12 cells mediated by retroviral vectors. Developmental Neuroscience. 12: 34-45. PMID 2105198 DOI: 10.1159/000111833 |
0.344 |
|
| 1990 |
Seizinger BR, Breakefield XO. The role of 'tumor suppressor' genes in neural tumors. Trends in Neurosciences. 13: 3-6. PMID 1688673 DOI: 10.1016/0166-2236(90)90050-K |
0.375 |
|
| 1989 |
Breakefield XO, Geller AI. Gene transfer into the nervous system. Molecular Neurobiology. 1: 339-71. PMID 3077063 DOI: 10.1007/BF02935741 |
0.378 |
|
| 1989 |
Breakefield XO. Combining CNS transplantation and gene transfer. Neurobiology of Aging. 10: 647-8; discussion 64. PMID 2812248 DOI: 10.1016/0197-4580(89)90167-X |
0.333 |
|
| 1989 |
Shimohama S, Rosenberg MB, Fagan AM, Wolff JA, Short MP, Breakefield XO, Friedmann T, Gage FH. Grafting genetically modified cells into the rat brain: characteristics of E. coli beta-galactosidase as a reporter gene. Brain Research. Molecular Brain Research. 5: 271-8. PMID 2501628 DOI: 10.1016/0169-328X(89)90061-2 |
0.32 |
|
| 1988 |
Rosenberg MB, Friedmann T, Robertson RC, Tuszynski M, Wolff JA, Breakefield XO, Gage FH. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science (New York, N.Y.). 242: 1575-8. PMID 3201248 DOI: 10.1126/Science.3201248 |
0.316 |
|
| 1988 |
Ozelius L, Hsu YPP, Bruns G, Powell JF, Chen S, Weyler W, Utterback M, Zucker D, Haines J, Trofatter JA, Conneally PM, Gusella JF, Breakefield XO. Human monoamine oxidase gene (MAOA): Chromosome position (Xp21-p11) and DNA polymorphism Genomics. 3: 53-58. PMID 2906043 DOI: 10.1016/0888-7543(88)90159-0 |
0.319 |
|
| 1988 |
Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons Science. 241: 1667-1669. PMID 2843986 DOI: 10.1126/Science.2843986 |
0.366 |
|
| 1987 |
Seizinger BR, Martuza RL, Rouleau G, Breakefield XO, Gusella JF. Models for inherited susceptibility to cancer in the nervous system: a molecular-genetic approach to neurofibromatosis. Developmental Neuroscience. 9: 144-53. PMID 3119309 DOI: 10.1159/000111618 |
0.363 |
|
| 1987 |
Rosenberg MB, Breakefield XO, Hawrot E. Targeting of Liposomes to Cells Bearing Nerve Growth Factor Receptors Mediated by Biotinylated Nerve Growth Factor Journal of Neurochemistry. 48: 865-875. PMID 3027260 DOI: 10.1111/J.1471-4159.1987.Tb05597.X |
0.306 |
|
| 1987 |
Seizinger BR, Rouleau GA, Lane AH, Farmer G, Ozelius LJ, Haines JL, Parry DM, Korf BR, Pericak-Vance MA, Faryniarz AG, Hobbs WJ, Iannazzi JA, Roy JC, Menon A, Bader JL, ... ... Breakefield XO, et al. Linkage analysis in von Recklinghausen neurofibromatosis (NF1) with DNA markers for chromosome 17 Genomics. 1: 346-348. PMID 2896628 DOI: 10.1016/0888-7543(87)90035-8 |
0.305 |
|
| 1986 |
Brockes JP, Breakefield XO, Martuza RL. Glial growth factor-like activity in Schwann cell tumors. Annals of Neurology. 20: 317-22. PMID 3767316 DOI: 10.1002/Ana.410200308 |
0.324 |
|
| 1986 |
Breakefield XO, Bressman SB, Kramer PL, Ozelius L, Moskowitz C, Tanzi R, Brin MF, Hobbs W, Kaufman D, Tobin A. Linkage analysis in a family with dominantly inherited torsion dystonia: exclusion of the pro-opiomelanocortin and glutamic acid decarboxylase genes and other chromosomal regions using DNA polymorphisms. Journal of Neurogenetics. 3: 159-75. PMID 3016220 DOI: 10.3109/01677068609106846 |
0.324 |
|
| 1986 |
Breakefield XO, Stern DF. Oncogenes in neural tumors Trends in Neurosciences. 9: 150-155. DOI: 10.1016/0166-2236(86)90051-2 |
0.352 |
|
| 1983 |
Breakefield XO, Hansen CR. Do DNA rearrangements occur in neuronal development? Clues from an inherited human disease Trends in Neurosciences. 6: 444-446. DOI: 10.1016/0166-2236(83)90215-1 |
0.343 |
|
| 1981 |
Hawkins M, Wallace DC, Eisenstadt JM, Breakefield XO. Expression of monoamine oxidase A and B activities in mouse cybrids and hybrids. Life Sciences. 28: 425-432. PMID 7219055 DOI: 10.1016/0024-3205(81)90089-8 |
0.347 |
|
| 1981 |
Pintar J, Barbosa J, Francke U, Castiglione C, Hawkins M, Breakefield X. Gene for monoamine oxidase type A assigned to the human X chromosome. The Journal of Neuroscience. 1: 166-175. DOI: 10.1523/Jneurosci.01-02-00166.1981 |
0.31 |
|
| 1979 |
Castrocosta MR, Breakefield XO. Distinct forms of monoamine oxidase expressed in hepatoma and HeLa cells in culture. Biochemical Pharmacology. 28: 525-528. PMID 426872 DOI: 10.1016/0006-2952(79)90246-6 |
0.307 |
|
| 1979 |
Walter U, Costa MR, Breakefield XO, Greengard P. Presence of free cyclic AMP receptor protein and regulation of its level by cyclic AMP in neuroblastoma-glioma hybrid cells. Proceedings of the National Academy of Sciences of the United States of America. 76: 3251-5. PMID 226964 DOI: 10.1073/pnas.76.7.3251 |
0.304 |
|
| 1978 |
Breakefield XO, Castiglione CM, Halaban R, Pawelek J, Shiman R. Phenylalanine hydroxylase in melanoma cells. Journal of Cellular Physiology. 94: 307-14. PMID 23386 DOI: 10.1002/JCP.1040940308 |
0.302 |
|
| 1975 |
Breakefield XO, Neale EA, Neale JH, Jacobowitz DM. Localized catecholamine storage associated with granules in murine neuroblastoma cells Brain Research. 92: 237-256. PMID 240485 DOI: 10.1016/0006-8993(75)90273-5 |
0.304 |
|
| 1974 |
Breakefield XO, Nirenberg MW. Selection for neuroblastoma cells that synthesize certain transmitters. Proceedings of the National Academy of Sciences of the United States of America. 71: 2530-3. PMID 4152249 DOI: 10.1073/Pnas.71.6.2530 |
0.547 |
|
| Show low-probability matches. |
